Table 3.
No. (%) of Patients | OR (95% CI) | P | OR (95% CI)* | P | |
---|---|---|---|---|---|
Never-smoker | |||||
CYP1A1 c.1384A>G (AA as referent; n=363) | |||||
EPHX1 c.337T>C (TT as referent; n=216) | |||||
TC + AG/GG | 20 | 1.29 (0.68–2.47) | 0.43 | 1.14 (0.57 – 2.3) | 0.7 |
CC + AG/GG | 10 | 2.67 (1.16–6.15) | 0.02 | 3.07 (1.2 – 7.81) | 0.02 |
TC/CC + AG/GG | 30 | 1.57 (0.87–2.82) | 0.13 | 1.46 (0.78 – 2.77) | 0.24 |
Ever-smoker | |||||
CYP1A1 c.1384A>G (AA as referent; n=336) | |||||
EPHX1 c.337T>C (TT as referent; n=164 ) | |||||
TC + AG/GG | 16 | 1.46 (0.66–3.26) | 0.35 | 1.66 (0.72 – 3.83) | 0.23 |
CC + AG/GG | 8 | 3.59 (1.33–9.65) | 0.01 | 3.33 (1.16 – 9.54) | 0.02 |
TC/CC + AG/GG | 24 | 1.82 (0.87–3.84) | 0.11 | 1.99 (0.91 – 4.34) | 0.08 |
Males | |||||
CYP1A1 c.1384A>G (AA as referent; n=415) | |||||
EPHX1 c.337T>C (TT as referent; n=221) | |||||
TC + AG/GG | 24 | 2.13 (1.07 – 4.26) | 0.03 | 2.21 (1.05 – 4.65) | 0.04 |
CC + AG/GG | 13 | 4.58 (2.0 – 10.44) | <0.001 | 4.53 (1.82 – 11.27) | 0.001 |
TC/CC + AG/GG | 37 | 2.63 (1.38 – 5.0) | 0.003 | 2.7 (1.35 – 5.4) | 0.005 |
Females | |||||
CYP1A1 c.1384A>G (AA as referent; n=284) | |||||
EPHX1 c.337T>C (TT as referent; n=159) | |||||
TC + AG/GG | 12 | 0.72 (0.34 – 1.55) | 0.41 | 0.75 (0.34 – 1.65) | 0.47 |
CC + AG/GG | 5 | 1.67 (0.57 – 4.94) | 0.35 | 1.76 (0.56 – 5.56) | 0.33 |
TC/CC + AG/GG | 17 | 0.87 ( 0.43 – 1.74) | 0.69 | 0.9 (0.43 – 1.85) | 0.77 |
OR adjusted for age, gender and race (White vs. other) for analysis stratified by smoking and age, race and smoking for analysis by gender